Overview

Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas

Status:
Active, not recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if an extended maintenance therapy with Rituximab in follicular and a maintenance therapy in other indolent and mantle cell lymphomas has advantages compared to a shorter or no maintenance therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Jurgen Barth
Collaborator:
Sponsor GmbH
Treatments:
Bendamustine Hydrochloride
Rituximab